Esperion Therapeutics, Inc. (ESPR) shares surged 56.25 percent to $3.1250 on Friday, gaining $1.1250, after the company announced a definitive acquisition agreement.
The stock is currently trading at $3.1250, compared to its previous close of $2.0000 on the Nasdaq. It opened at $3.1350 and has traded in a narrow range of $3.1200 to $3.1400, with volume spiking to 90,131,752 shares.
The funds managed by ARCHIMED will acquire Esperion in a deal valued at up to approximately $1.1 billion. Under the terms, shareholders will receive $3.16 per share in cash at closing, representing a 58 percent premium to the prior closing price, along with potential additional milestone payments of up to $100 million tied to future sales performance.
The stock has traded between $0.6900 and $4.1800 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.